These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8888658)

  • 41. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
    Opatrný K; Opatrná S; Vít L; Opatrný K
    Am J Nephrol; 1998; 18(3):186-92. PubMed ID: 9627033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
    Hamsten A; Syvänne M; Silveira A; Luong LA; Nieminen MS; Humphries S; Frick MH; Taskinen MR
    Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive value of fibrinolytic factors in coronary heart disease.
    Wiman B
    Scand J Clin Lab Invest Suppl; 1999; 230():23-31. PubMed ID: 10389198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease.
    Sakamoto T; Kaikita K; Miyamoto S; Kojima S; Sugiyama S; Yoshimura M; Ogawa H
    Circ J; 2004 Mar; 68(3):232-5. PubMed ID: 14993778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M; Miyashita C
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1.
    Andreotti F; Kluft C; Davies GJ; Huisman LG; de Bart AC; Maseri A
    Am J Cardiol; 1991 Nov; 68(13):1295-9. PubMed ID: 1951115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
    Hadigan C; Meigs JB; Rabe J; D'Agostino RB; Wilson PW; Lipinska I; Tofler GH; Grinspoon SS;
    J Clin Endocrinol Metab; 2001 Feb; 86(2):939-43. PubMed ID: 11158071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women.
    Koh KK
    Int J Hematol; 2002 Aug; 76 Suppl 2():44-6. PubMed ID: 12430899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
    Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of endurance training on the circadian rhythm of fibrinolysis in men and women.
    Chandler WL; Schwartz RS; Stratton JR; Vitiello MV
    Med Sci Sports Exerc; 1996 Jun; 28(6):647-55. PubMed ID: 8784750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of local availability of active tissue-type plasminogen activator in vivo in man.
    Hrafnkelsdottir T; Gudnason T; Wall U; Jern C; Jern S
    J Thromb Haemost; 2004 Nov; 2(11):1960-8. PubMed ID: 15550028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
    Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
    Agents Actions Suppl; 1992; 38 ( Pt 2)():342-9. PubMed ID: 1462840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women.
    Svendsen OL; Hassager C; Christiansen C; Nielsen JD; Winther K
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):381-5. PubMed ID: 8630663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina.
    Smith AM; English KM; Malkin CJ; Jones RD; Jones TH; Channer KS
    Eur J Endocrinol; 2005 Feb; 152(2):285-91. PubMed ID: 15745938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
    Lockwood CJ; Krikun G; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects.
    Lottermoser K; Hertfelder HJ; Wehling M; Schiermeyer B; Vetter H; Düsing R
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):357-60. PubMed ID: 11967823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.